ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

Roche’s attempt to muscle in on paroxysmal nocturnal hemoglobinuria (PNH) is on track. The subcutaneous anti-C5 recycling antibody crovalimab improved outcomes in a Chinese phase 3 trial, giving the Big Pharma a boost as it closes in on data from its showdown with AstraZeneca’s Soliris.